Reduced dose prednisone plus eltrombopag for the treatment of newly diagnosed adult primary immune thrombocytopenia: A prospective, multicentre, phase 2 clinical trial
Authors:
Open Access
- 15 September 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 207 (6) , 2617-2621
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- How we treat primary immune thrombocytopenia in adultsJournal of Hematology & Oncology, 2023
- All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trialThe Lancet Haematology, 2021
- Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatmentAmerican Journal of Hematology, 2020
- Safety and efficacy of eltrombopag plus pulsed dexamethasone as first‐line therapy for immune thrombocytopeniaBritish Journal of Haematology, 2020
- American Society of Hematology 2019 guidelines for immune thrombocytopeniaBlood Advances, 2019
- Updated international consensus report on the investigation and management of primary immune thrombocytopeniaBlood Advances, 2019
- Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adultsBlood, 2014
- 成人原发免疫性血小板减少症诊断与治疗中国指南（2020年版）